Sio Gene Therapies, Inc. (SIOX): Price and Financial Metrics
SIOX Price/Volume Stats
| Current price | $0.48 | 52-week high | $0.50 |
| Prev. close | $0.47 | 52-week low | $0.25 |
| Day low | $0.45 | Volume | 40,400 |
| Day high | $0.48 | Avg. volume | 107,821 |
| 50-day MA | $0.39 | Dividend yield | N/A |
| 200-day MA | $0.39 | Market Cap | 34.87M |
SIOX Stock Price Chart Interactive Chart >
Sio Gene Therapies, Inc. (SIOX) Company Bio
Sio Gene Therapies, Inc. operates as a clinical-stage biopharmaceutical company. The Company develops gene therapies that transform the treatment of serious neurodegenerative diseases. Sio Gene Therapies serves customers worldwide.
Latest SIOX News From Around the Web
Below are the latest news stories about SIO GENE THERAPIES INC that investors may wish to consider to help them evaluate SIOX as an investment opportunity.
Sio Gene Therapies Announces Fiscal Third Quarter 2022 Financial Results– Three-Month and Nine-Month Losses decline by 84.2% and 73.5%, respectively – Operating Cash Outflows for the Nine Months Ended December 31, 2022 decreased by $23.8 million or 56% versus the prior year period – $46.1 million of cash and cash equivalents as of December 31, 2022, a strong cash position as the Company prepares for liquidation and dissolution, subject to stockholder approval NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX) today provided financial |
Sio Gene Therapies Inc. Announces Board Approval of Plan of Complete Liquidation and DissolutionNEW YORK, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (Nasdaq:SIOX) today announced that its Board of Directors has determined, after extensive and careful consideration of potential strategic alternatives, that it is in the best interests of the Company and its shareholders to dissolve the Company and liquidate its assets, including its subsidiaries. "After evaluating the Company's strategic options, the Board of Directors unanimously concluded that it is in the best interests of |
Sio Gene Therapies Announces Fiscal Second Quarter 2022 Financial Results- Three-Month and Six-Month Losses decline by 85.5% and 65.3%, respectively - Operating Cash Outflows for the Six Months Ended September 30, 2022 decreased by $8.1 million or 37% versus the prior year period - Strong cash position with $49.86 million of cash and cash equivalents as of September 30, 2022, expected to provide cash runway beyond December 2023 NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX) today provided financial results for its fiscal second qua |
Sio Gene Therapies Announces Fiscal First Quarter 2022 Financial Results— Strong cash position with $54.8 million of cash and cash equivalents as of June 30, 2022, expected to provide cash runway beyond August 2023 NEW YORK, N.Y. and DURHAM, N.C., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX) today provided financial results for its fiscal first quarter ended June 30, 2022. “Our financial results show the beneficial effects on operating expenses and cash resulting from the termination of the licenses to our three clinical-stage programs an |
Sio Gene Therapies Announces Fiscal Year 2021 Year-End Financial ResultsNEW YORK and DURHAM, N.C., June 14, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX) today provided financial results for its fiscal year ended March 31, 2022. Fiscal Fourth Quarter Financial Summary For the fourth fiscal quarter ended March 31, 2022, research and development expenses were $12.6 million, an increase of $4.4 million compared to the prior year quarter. The current period increase was primarily related to increased AXO-AAV-GM1 clinical trial material manufacturing ex |
SIOX Price Returns
| 1-mo | N/A |
| 3-mo | 23.39% |
| 6-mo | 21.21% |
| 1-year | 16.79% |
| 3-year | -81.03% |
| 5-year | N/A |
| YTD | 29.73% |
| 2023 | -14.94% |
| 2022 | -66.28% |
| 2021 | -53.60% |
| 2020 | -45.70% |
| 2019 | N/A |
Loading social stream, please wait...